Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins

Abstract SARS-CoV-2 variants of concern (VOCs) have emerged worldwide, with implications on the spread of the pandemic. Characterizing the cross-reactivity of antibodies against these VOCs is necessary to understand the humoral response of non-hospitalized individuals previously infected with SARS-C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maryam Hojjat Jodaylami, Abdelhadi Djaïleb, Pierre Ricard, Étienne Lavallée, Stella Cellier-Goethebeur, Megan-Faye Parker, Julien Coutu, Matthew Stuible, Christian Gervais, Yves Durocher, Florence Desautels, Marie-Pierre Cayer, Marie Joëlle de Grandmont, Samuel Rochette, Danny Brouard, Sylvie Trottier, Denis Boudreau, Joelle N. Pelletier, Jean-Francois Masson
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a83b93cecef64506a2384cd39a901c51
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a83b93cecef64506a2384cd39a901c51
record_format	dspace
spelling	oai:doaj.org-article:a83b93cecef64506a2384cd39a901c512021-11-14T12:24:30ZCross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins10.1038/s41598-021-00844-z2045-2322https://doaj.org/article/a83b93cecef64506a2384cd39a901c512021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-00844-zhttps://doaj.org/toc/2045-2322Abstract SARS-CoV-2 variants of concern (VOCs) have emerged worldwide, with implications on the spread of the pandemic. Characterizing the cross-reactivity of antibodies against these VOCs is necessary to understand the humoral response of non-hospitalized individuals previously infected with SARS-CoV-2, a population that remains understudied. Thirty-two SARS-CoV-2-positive (PCR-confirmed) and non-hospitalized Canadian adults were enrolled 14–21 days post-diagnosis in 2020, before the emergence of the B.1.351 (also known as Beta), B.1.617.2 (Delta) and P.1 (Gamma) VOCs. Sera were collected 4 and 16 weeks post-diagnosis. Antibody levels and pseudo-neutralization of the ectodomain of SARS-CoV-2 spike protein/human ACE-2 receptor interaction were analyzed with native, B.1.351, B.1.617.2 and P.1 variant spike proteins. Despite a lower response observed for the variant spike proteins, we report evidence of a sustained humoral response against native, B.1.351, B.1.617.2 and P.1 variant spike proteins among non-hospitalized Canadian adults. Furthermore, this response inhibited the interaction between the spike proteins from the different VOCs and ACE-2 receptor for ≥ 16 weeks post-diagnosis, except for individuals aged 18–49 years who showed no inhibition of the interaction between B.1.617.1 or B.1.617.2 spike and ACE-2. Interestingly, the affinity (KD) measured between the spike proteins (native, B.1.351, B.1.617.2 and P.1) and antibodies elicited in sera of infected and vaccinated (BNT162b2 and ChAdOx1 nCoV-19) individuals was invariant. Relative to sera from vaccine-naïve (and previously infected) individuals, sera from vaccinated individuals had higher antibody levels (as measured with label-free SPR) and more efficiently inhibited the spike–ACE-2 interactions, even among individuals aged 18–49 years, showing the effectiveness of vaccination.Maryam Hojjat JodaylamiAbdelhadi DjaïlebPierre RicardÉtienne LavalléeStella Cellier-GoethebeurMegan-Faye ParkerJulien CoutuMatthew StuibleChristian GervaisYves DurocherFlorence DesautelsMarie-Pierre CayerMarie Joëlle de GrandmontSamuel RochetteDanny BrouardSylvie TrottierDenis BoudreauJoelle N. PelletierJean-Francois MassonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Maryam Hojjat Jodaylami Abdelhadi Djaïleb Pierre Ricard Étienne Lavallée Stella Cellier-Goethebeur Megan-Faye Parker Julien Coutu Matthew Stuible Christian Gervais Yves Durocher Florence Desautels Marie-Pierre Cayer Marie Joëlle de Grandmont Samuel Rochette Danny Brouard Sylvie Trottier Denis Boudreau Joelle N. Pelletier Jean-Francois Masson Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
description	Abstract SARS-CoV-2 variants of concern (VOCs) have emerged worldwide, with implications on the spread of the pandemic. Characterizing the cross-reactivity of antibodies against these VOCs is necessary to understand the humoral response of non-hospitalized individuals previously infected with SARS-CoV-2, a population that remains understudied. Thirty-two SARS-CoV-2-positive (PCR-confirmed) and non-hospitalized Canadian adults were enrolled 14–21 days post-diagnosis in 2020, before the emergence of the B.1.351 (also known as Beta), B.1.617.2 (Delta) and P.1 (Gamma) VOCs. Sera were collected 4 and 16 weeks post-diagnosis. Antibody levels and pseudo-neutralization of the ectodomain of SARS-CoV-2 spike protein/human ACE-2 receptor interaction were analyzed with native, B.1.351, B.1.617.2 and P.1 variant spike proteins. Despite a lower response observed for the variant spike proteins, we report evidence of a sustained humoral response against native, B.1.351, B.1.617.2 and P.1 variant spike proteins among non-hospitalized Canadian adults. Furthermore, this response inhibited the interaction between the spike proteins from the different VOCs and ACE-2 receptor for ≥ 16 weeks post-diagnosis, except for individuals aged 18–49 years who showed no inhibition of the interaction between B.1.617.1 or B.1.617.2 spike and ACE-2. Interestingly, the affinity (KD) measured between the spike proteins (native, B.1.351, B.1.617.2 and P.1) and antibodies elicited in sera of infected and vaccinated (BNT162b2 and ChAdOx1 nCoV-19) individuals was invariant. Relative to sera from vaccine-naïve (and previously infected) individuals, sera from vaccinated individuals had higher antibody levels (as measured with label-free SPR) and more efficiently inhibited the spike–ACE-2 interactions, even among individuals aged 18–49 years, showing the effectiveness of vaccination.
format	article
author	Maryam Hojjat Jodaylami Abdelhadi Djaïleb Pierre Ricard Étienne Lavallée Stella Cellier-Goethebeur Megan-Faye Parker Julien Coutu Matthew Stuible Christian Gervais Yves Durocher Florence Desautels Marie-Pierre Cayer Marie Joëlle de Grandmont Samuel Rochette Danny Brouard Sylvie Trottier Denis Boudreau Joelle N. Pelletier Jean-Francois Masson
author_facet	Maryam Hojjat Jodaylami Abdelhadi Djaïleb Pierre Ricard Étienne Lavallée Stella Cellier-Goethebeur Megan-Faye Parker Julien Coutu Matthew Stuible Christian Gervais Yves Durocher Florence Desautels Marie-Pierre Cayer Marie Joëlle de Grandmont Samuel Rochette Danny Brouard Sylvie Trottier Denis Boudreau Joelle N. Pelletier Jean-Francois Masson
author_sort	Maryam Hojjat Jodaylami
title	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
title_short	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
title_full	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
title_fullStr	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
title_full_unstemmed	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
title_sort	cross-reactivity of antibodies from non-hospitalized covid-19 positive individuals against the native, b.1.351, b.1.617.2, and p.1 sars-cov-2 spike proteins
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a83b93cecef64506a2384cd39a901c51
work_keys_str_mv	AT maryamhojjatjodaylami crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT abdelhadidjaileb crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT pierrericard crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT etiennelavallee crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT stellacelliergoethebeur crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT meganfayeparker crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT juliencoutu crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT matthewstuible crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT christiangervais crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT yvesdurocher crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT florencedesautels crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT mariepierrecayer crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT mariejoelledegrandmont crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT samuelrochette crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT dannybrouard crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT sylvietrottier crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT denisboudreau crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT joellenpelletier crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins AT jeanfrancoismasson crossreactivityofantibodiesfromnonhospitalizedcovid19positiveindividualsagainstthenativeb1351b16172andp1sarscov2spikeproteins
_version_	1718429248528580608

Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins

Ejemplares similares